Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
AVENGER 500
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
- NCT03504423 ↗
- Completed
- Cornerstone Pharmaceuticals
- Standard
We haven't built an HCP commentary report on AVENGER 500 (devimistat (CPI-613) in metastatic adenocarcinoma of the pancreas) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AVENGER 500 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- CPI 613, mFolfirinox; Folfirinox
- Arms
- CPI-613, mFolfirinox · Experimental
- Folfirinox · Active comparator
- Enrollment
- 528
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Nov 9, 2018
- Primary completion
- Aug 16, 2021
- Results posted
- Yes
- Registry record
- NCT03504423 · updated Jan 3, 2023
Publications
linked from the registry- Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. J Clin Oncol. 2024 Nov;42(31):3692-3701. doi: 10.1200/JCO.23.02659. Epub 2024 Aug 1. PubMed 39088774
- Liu N, Yan M, Tao Q, Wu J, Chen J, Chen X, Peng C. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis. J Immunother Cancer. 2023 Sep;11(9):e007146. doi: 10.1136/jitc-2023-007146. PubMed 37678921
- Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E. A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol. 2019 Oct;15(28):3189-3196. doi: 10.2217/fon-2019-0209. Epub 2019 Sep 12. PubMed 31512497